Regional nodal irradiation in early-stage breast cancer

New England Journal of Medicine

Volumn 373, Issue 4, 2015, Pages 307-316

  Whelan, Timothy J ^a   Olivotto, Ivo A ^b,c   Parulekar, Wendy R ^d   Ackerman, Ida ^e   Chua, Boon H ^m   Nabid, Abdenour ^f   Vallis, Katherine A ⁿ   White, Julia R ^o   Rousseau, Pierre ^g   Fortin, Andre ^h   Pierce, Lori J ^p   Manchul, Lee ⁱ   Chafe, Susan ^j   Nolan, Maureen C ^k   Craighead, Peter ^b   Bowen, Julie ^l   McCready, David R ⁱ   Pritchard, Kathleen I ^e   Gelmon, Karen ^c   Murray, Yvonne ^d   Chapman, Judy Anne W ^d   Chen, Bingshu E ^d   Levine, Mark N ^a   more..

^a MCMASTER UNIVERSITY   (Canada)

^b TOM BAKER CANCER CENTRE   (Canada)

^c BRITISH COLUMBIA CANCER AGENCY   (Canada)

^d QUEEN S UNIVERSITY   (Canada)

^e UNIVERSITY OF TORONTO   (Canada)

^f CENTRE HOSPITALIER UNIVERSITAIRE DE SHERBROOKE   (Canada)

^g UNIVERSITÉ DE MONTRÉAL   (Canada)

^h LAVAL UNIVERSITY   (Canada)

ⁱ PRINCESS MARGARET HOSPITAL   (Canada)

^j CROSS CANCER INSTITUTE   (Canada)

^k Nova Scotia Cancer Centre   (Canada)

^l Northeastern Ontario Regional Cancer Centre   (Canada)

^m PETER MACCALLUM CANCER CENTRE   (Australia)

ⁿ UNIVERSITY OF OXFORD   (United Kingdom)

^o THE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER   (United States)

^p UNIVERSITY OF MICHIGAN COMPREHENSIVE CANCER CENTER   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE DERIVATIVE; AROMATASE INHIBITOR; TAMOXIFEN; TAXANE DERIVATIVE; ANTINEOPLASTIC AGENT;

ADULT; ARTICLE; BREAST CARCINOMA; CANCER ADJUVANT THERAPY; CANCER HORMONE THERAPY; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER STAGING; CONTROLLED STUDY; DISEASE FREE SURVIVAL; FATIGUE; FEMALE; FOLLOW UP; HEART INFARCTION; HEART LEFT VENTRICLE FAILURE; HEART MUSCLE ISCHEMIA; HEART SUPRAVENTRICULAR ARRHYTHMIA; HIGH RISK PATIENT; HUMAN; INTERSTITIAL PNEUMONIA; LYMPHEDEMA; MAJOR CLINICAL STUDY; MOTOR NEUROPATHY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PARTIAL MASTECTOMY; PERICARDIAL EFFUSION; PRIORITY JOURNAL; RADIATION DERMATITIS; REGIONAL NODAL IRRADIATION; SENSORY NEUROPATHY; TELANGIECTASIA; WHOLE BREAST IRRADIATION; ADVERSE EFFECTS; AGED; BREAST NEOPLASMS; CLINICAL TRIAL; LYMPHATIC METASTASIS; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; MULTIMODALITY CANCER THERAPY; NEOPLASM RECURRENCE, LOCAL; RADIATION DOSE; RANDOMIZED CONTROLLED TRIAL; RISK; SEGMENTAL MASTECTOMY; SENTINEL LYMPH NODE BIOPSY; SURVIVAL; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; COMBINED MODALITY THERAPY; FEMALE; FOLLOW-UP STUDIES; HUMANS; LYMPHATIC METASTASIS; MASTECTOMY, SEGMENTAL; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; RADIATION DOSAGE; RADIOTHERAPY; RISK; SENTINEL LYMPH NODE BIOPSY; SURVIVAL ANALYSIS;

EID: 84937943242     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMoa1415340     Document Type: Article

References (21)

1. Fisher B, Bauer M, Margolese R, et al. Five-year results of a randomized clinical trial comparing total mastectomy and segmental mastectomy with or without radiation in the treatment of breast cancer. N Engl J Med 1985; 312: 665-73.
2. Veronesi U, Luini A, Del Vecchio M, et al. Radiotherapy after breast-preserving surgery in women with localized cancer of the breast. N Engl J Med 1993; 328: 1587-91.
3. Clark RM, Whelan T, Levine M, et al. Randomized clinical trial of breast irradiation following lumpectomy and axillary dissection for node-negative breast cancer: an update. J Natl Cancer Inst 1996;88:1659-64.
4. Ragaz J, Jackson SM, Le N, et al. Adjuvant radiotherapy and chemotherapy in node-positive premenopausal women with breast cancer. N Engl J Med 1997; 337: 956-62.
5. Overgaard M, Hansen PS, Overgaard J, et al. Postoperative radiotherapy in high-risk premenopausal women with breast cancer who receive adjuvant chemotherapy: Danish Breast Cancer Cooperative Group 82b Trial. N Engl J Med 1997;337:949-55.
6. Overgaard M, Jensen MB, Overgaard J, et al. Postoperative radiotherapy in high-risk postmenopausal breast-cancer patients given adjuvant tamoxifen: Danish Breast Cancer Cooperative Group DBCG 82c randomised trial. Lancet 1999; 353: 1641-8.
7. Recht A, Siddon RL, Kaplan WD, Andersen J W, Harris JR. Three-dimensional internal mammary lymphoscintigraphy: implications for radiation therapy treatment planning for breast carcinoma. Int J Radiat Oncol Biol Phys 1988; 14: 477-81.
8. Pocock SJ. Clinical trials: a practical approach. New York: John Wiley and Sons, 1983.
9. Whelan TJ, Olivotto I, Ackerman I, et al. NCIC-CTG MA.20: an intergroup trial of regional nodal irradiation in early breast cancer. J Clin Oncol 2011; 29: Suppl: LBA1003.
10. Ceilley E, Jagsi R, Goldberg S, et al. Radiotherapy for invasive breast cancer in North America and Europe: results of a survey. Int J Radiat Oncol Biol Phys 2005; 61: 365-73.
11. Huang O, Wang L, Shen K, et al. Breast cancer subpopulation with high risk of internal mammary lymph nodes metastasis: analysis of 2, 269 Chinese breast cancer patients treated with extended radical mastectomy. Breast Cancer Res Treat 2008;107:379-87.
12. Veronesi U, Arnone P, Veronesi P, et al. The value of radiotherapy on metastat-ic internal mammary nodes in breast cancer: results on a large series. Ann Oncol 2008;19:1553-60.
13. McGale P, Taylor C, Correa C, et al. Effect of radiotherapy after mastectomy and axillary surgery on 10-year recurrence and 20-year breast cancer mortality: meta-analysis of individual patient data for 8135 women in 22 randomised trials. Lancet 2014;383:2127-35.
14. Poortmans P, Collette S, Kirkove C, et al. Internal mammary and medial supra-clavicular irradiation in breast cancer. N Engl J Med 2015; 373:317-27.
15. Wang R, Lagakos SW, Ware JH, Hunter DJ, Drazen JM. Statistics in medicine-reporting of subgroup analyses in clinical trials. N Engl J Med 2007; 357: 2189-94.
16. Kyndi M, Sørensen FB, Knudsen H, Overgaard M, Nielsen HM, Overgaard J. Estrogen receptor, progesterone receptor, HER-2, and response to postmastectomy radiotherapy in high-risk breast cancer: the Danish Breast Cancer Cooperative Group. J Clin Oncol 2008; 26: 1419-26.
17. Mamounas EP, Tang G, Fisher B, et al. Association between the 21-gene recurrence score assay and risk of locoregional recurrence in node-negative, estrogen receptor-positive breast cancer: results from NSABP B-14 and NSABP B-20. J Clin Oncol 2010;28:1677-83.
18. Voduc KD, Cheang MCU, Tyldesley S, Gelmon K, Nielsen TO, Kennecke H. Breast cancer subtypes and the risk of local and regional relapse. J Clin Oncol 2010;28:1684-91.
19. Højris I, Andersen J, Overgaard M, Overgaard J. Late treatment-related morbidity in breast cancer patients randomized to postmastectomy radiotherapy and systemic treatment versus systemic treatment alone. Acta Oncol 2000; 39: 355-72.
20. Cook R, Farewell VT. Multiplicity considerations in the design and analysis of clinical trials. J R Stat Soc Ser A Stat Soc 1996;159:93-110.
21. Giuliano AE, Hunt KK, Ballman KV, et al. Axillary dissection vs no axillary dissection in women with invasive breast cancer and sentinel node metastasis: a randomized clinical trial. JAMA 2011; 305: 569-75.